Immunovant (IMVT)
(Real Time Quote from BATS)
$29.29 USD
-0.30 (-1.01%)
Updated Sep 20, 2024 03:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMVT 29.29 -0.30(-1.01%)
Will IMVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
Other News for IMVT
Roivant disposal deal good for sentiment and cash burn, says Jefferies
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Roivant Provides Update on Graves? Disease Development Program
Immunovant stock falls 8% amid Graves' disease program update
Immunovant Provides Update on Graves? Disease Development Program